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Significance and impact of the study 15 
Manuka honey is known to have a broad spectrum of antimicrobial activity, with the bacterial 16 
cell wall being suggested as a predominant site of action.  This study has demonstrated that 17 
Manuka honey has activity against Ureaplasma spp., a genus of cell-wall free bacteria which 18 
are intrinsically resistant to many available antibiotics making treatment inherently difficult.  19 
This is the first report of the antimicrobial activity of Manuka honey against a bacterial 20 
pathogen, in the absence of a cell well and opens scope for the use of components of Manuka 21 
honey as a therapeutic among Ureaplasma infections. 22 
 23 
Abstract 24 
The susceptibility of the cell-wall free bacterial pathogens Ureaplasma spp. to Manuka honey 25 
was examined.   The minimum inhibitory concentration (MIC) of Manuka honey for four 26 
Ureaplasma urealyticum and four Ureaplasma parvum isolates was determined.  Sensitivity 27 
to honey was also compared to clinical isolates with resistance to tetracycline, macrolide and 28 
fluoroquinolone antibiotics.  Finally step-wise resistance training was utilised in an attempt 29 
to induce increased tolerance to honey.  The MIC was dependent on the initial bacterial load 30 
with 7.5 % and 18.0 % w/v honey required to inhibit U. urealyticum at 1 and 106 colour 31 
changing units (CCU), respectively, and 4.8 % and 15.3 % w/v required to inhibit U. parvum at 32 
1 and 106 CCU, respectively. MIC values were consistently lower for U. parvum compared with 33 
U. urealyticum.  Antimicrobial activity was seen against tetracycline resistant, erythromycin 34 
resistant and ciprofloxacin resistant isolates at 105 CCU.  No resistance to honey was observed 35 
with fifty consecutive challenges at increasing concentrations of honey.  This is the first report 36 
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of the antimicrobial activity of Manuka honey against a cell-wall free bacterial pathogen.  The 37 
antimicrobial activity was retained against antibiotic resistant strains and it was not possible 38 
to generate resistant mutants. 39 
 40 
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Introduction 44 
Ureaplasma spp. are a genus of bacteria of clinical relevance strongly linked with preterm 45 
birth and subsequent development of neonatal complications such as bronchopulmonary 46 
dysplasia, intraventricular haemorrhaging and necrotising enterocolitis (Viscardi, 2014).  47 
Additionally these pathogens are becoming recognised in sexual health (Zhang et al., 2014, 48 
Ondondo et al., 2010) and immune compromised transplant patients (Bharat et al., 2015).  49 
The unique physiology of these organisms results in high levels of intrinsic resistance to many 50 
clinically available antibiotics.  For example, the absence of a peptidoglycan cell wall renders 51 
these organisms resistant to all beta-lactam and glycopeptide antibiotics.  Only a limited 52 
number of antimicrobial classes are available for treatment including the macrolides, 53 
tetracyclines, fluoroquinolones and chloramphenicols.  With respect to infection during 54 
pregnancy and among preterm neonates these options are further limited due to host toxicity 55 
issues.  Tetracyclines are associated with deposition in growing teeth and bones whereas 56 
systemic administration of chloramphenicol is associated with “Grey baby” syndrome. 57 
Further complications arise as a result of isolates harbouring acquired resistance to the 58 
limited number of available antibiotics, with exception to chloramphenicol (Beeton et al., 59 
2015, Beeton et al., 2009b).  For these reasons alternatives are urgently required.   60 
 61 
Manuka honey has been shown to be a promising natural product with potent antimicrobial 62 
activity against pathogens such as Staphylococcus aureus and Pseudomonas 63 
aeruginosa.(Jenkins et al., 2011, Jenkins et al., 2012)  Unlike many traditional antibiotics which 64 
have a single site of action, honey has been suggested to have multiple antimicrobial 65 
components such as hydrogen peroxide, high levels of sugars, and methylglyoxal (Maddocks 66 
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and Jenkins, 2013).  Due to the multifaceted antimicrobial nature of this product it has been 67 
difficult to generate resistance in vitro (Cooper et al., 2010). 68 
 69 
Here we present data demonstrating the first report of antimicrobial activity of Manuka 70 
honey against a cell-wall free bacterial pathogen.  Additionally, we show no increase in 71 
susceptibility for clinical isolates characterised to have known mechanisms of antibiotic 72 
resistance, nor could resistance to honey be induced with repeated challenge of strains with 73 
concentrations of Manuka honey just below the MIC with classic in vitro step-wise training. 74 
 75 
Results and discussion 76 
A total of eight antibiotic susceptible Ureaplasma strains were initially examined for baseline 77 
susceptibility to Manuka honey using the modified broth microdilution method. For both U. 78 
urealyticum and U. parvum the percentage of Manuka honey required to yield inhibition 79 
increased in relation to the increase in initial inoculum (from 7.5% at 1 CCU to 18.0% at 106 80 
CCU for U. urealyticum and 4.8% at 1 CCU to 15.3% at 106 for U. parvum) (Table 1).  At the 81 
Clinical & Laboratory Standards Institute (CLSI) recommended inoculum of 104 - 105 for testing 82 
antimicrobials against Ureaplasma spp., the mean MIC for U. urealyticum was higher than 83 
that of U. parvum (13.5 vs 12.7 at 104 and 16.7 vs 15.8 at 105), but this difference was not 84 
statistically significant (p = 0.49). Following the establishment of baseline MIC values for 85 
Manuka honey against both U. urealyticum and U. parvum, the activity was then assessed 86 
against a small representative collection of antibiotic resistant strains.  No increase in MIC 87 
was noted for any resistant strain at the recommended 104 or 105 CCU relative to the matched 88 
inoculum for each respective antibiotic susceptible species (Table 2).  The antibiotic 89 
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susceptible strain HPA5 was serially passaged in sub-inhibitory concentrations of Manuka 90 
honey in an attempt to generate honey resistant isolates.  After 50 serial passages no 91 
elevation in Manuka honey MIC was noted (data not shown).  92 
 93 
The purpose of this study was to evaluate the antimicrobial activity of Manuka honey against 94 
a panel of clinical and laboratory strains of Ureaplasma spp.  From this we report the first 95 
example of antimicrobial activity of Manuka honey against a cell-wall free bacterial pathogen 96 
as well as retention of activity against clinically relevant antibiotic resistant strains.  Data 97 
available to date on the antimicrobial activity of Manuka honey has been generated in respect 98 
to typical bacterial pathogens such as S. aureus and P. aeruginosa (Jenkins et al., 2011, 99 
Camplin and Maddocks, 2014).  It has been suggested that one of the primary mechanisms of 100 
action of Manuka honey is targeting the cell wall murein hydrolase therefore disrupting 101 
cellular division (Jenkins et al., 2011).   As a result of reductive evolution ureaplasmas have 102 
lost the biosynthetic capabilities to synthesise the peptidoglycan cell wall.  From the data 103 
presented here we can speculate there are additional cellular targets other than the cell wall 104 
which leads to the antimicrobial activity, which reflects that previously suggested by Jenkins 105 
et al., (Jenkins et al., 2014).  In addition non-specific effects as a result of osmotic imbalances 106 
may have contributed to the antimicrobial activity. The MIC values for both Ureaplasma spp. 107 
were lower than those reported for the ATCC 9027 strain of P. aeruginosa (25.6 % w/v), yet 108 
comparable to a clinical P. aeruginosa isolate (15.3 % w/v),(Camplin and Maddocks, 2014) but 109 
were much higher than those previously reported for S. aureus <6 % w/v (Jenkins et al., 2012).  110 
These subtle differences may be due to the sites of action upon the pathogen in question, 111 
such as the cell wall in S. aureus, or differences in the Unique Manuka Factor between batches 112 
of honey examined.  When examining the MIC values between the Ureaplasma spp. we noted 113 
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that U. urealyticum had consistently higher MIC values at the CLSI recommended inoculum of 114 
104 to 105 when compared with U. parvum.  Although this was not a statistically significant 115 
difference, this reflects the observations in species difference seen when examining the 116 
activity of antibiotics against these pathogens (Beeton et al., 2016). Of clinical relevance was 117 
the observation that bacterial load played a substantial role in the MIC for both U. parvum 118 
and U. urealyticum.  Low grade infections would be treatable with much lower concentrations 119 
of honey, where as those with high titres, as seen clinically, would require much higher 120 
concentrations (Beeton et al., 2016).  Antibiotic resistant strains have been reported for the 121 
major classes of antibiotics effective against ureaplasmas, most notably the macrolides, 122 
tetracyclines and fluoroquinolones (Beeton et al., 2009b, Beeton et al., 2015).  For this reason 123 
we examined the antimicrobial activity of honey against a panel of antibiotic resistant clinical 124 
isolates.  We observed retention of antimicrobial activity against these isolates suggesting no 125 
cross-resistance from either antibiotic resistance mechanism or the activity of honey.  This is 126 
of significance in the case of preterm neonatal infections where macrolides are regarded the 127 
predominant antibiotic class of choice.   Pereyre et al. 2007, have previously demonstrated 128 
the ease by which ureaplasmas can acquire point mutations resulting in the development of 129 
resistance following exposure to macrolides via step wise resistance training (Pereyre et al., 130 
2007).  Similarly resistance to fluoroquinolones among Ureaplasma spp. results from the 131 
accumulation of mutations in the quinolone resistance determining regions (Beeton et al., 132 
2009a).  The data presented here demonstrated that it was not possible to generate isolates 133 
with an increased honey MIC following a similar time frame in which macrolide resistance was 134 
generated (Pereyre et al., 2007).  This is likely due to the suggested multiple antimicrobial 135 
agents present with in Manuka honey (Maddocks and Jenkins, 2013).  The inability to 136 
generate mutants is in line with previous reports for S. aureus and P. aeruginosa although a 137 
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report by Camplin and Maddocks demonstrated an increase in MIC for P. aeruginosa isolates 138 
recovered from honey treated in vitro biofilms (Cooper et al., 2010, Camplin and Maddocks, 139 
2014).  140 
 141 
In summary we have successfully demonstrated antimicrobial activity of Manuka honey 142 
against a bacterial pathogen with high levels of intrinsic and acquired antibiotic resistance in 143 
the absence of a cell wall.  The mechanisms by which Manuka honey exerts antimicrobial 144 
activity in this atypical bacterial pathogen of increasing clinical significance warrants further 145 
investigation. 146 
 147 
Materials and methods 148 
A total of eight antibiotic susceptible Ureaplasma strains were examined.  These comprised 149 
of four U. urealyticum including two clinical isolates (HPA99 and W11) and two reference 150 
strains (ATCC 27814 SV2 and ATCC 27618 SV8), in addition four U. parvum including two 151 
clinical isolates (HPA2 and HPA5) and two reference strains (ATCC 700970 SV3 and ATCC 152 
27818 SV6).  Representative antibiotic resistant strains ATCC 33175 SV9 (tetracycline 153 
resistant), UHWO10 (erythromycin resistant) and HPA116 (ciprofloxacin resistant) were 154 
included (Beeton et al., 2009b, Beeton et al., 2015).  All Ureaplasma isolates were grown in 155 
Ureaplasma selective media purchased from Mycoplasma Experience (Surrey, UK).  156 
Susceptibility to Activon 100% Medical Grade Manuka honey, purchased from Advancis 157 
Medical (Nottinghamshire, UK), was determined using CLSI M43-A guidelines for 158 
antimicrobial susceptibility testing for human mycoplasmas. In brief, a dilution gradient of 159 
honey prepared in Ureaplasma Selective Media from 20 % w/v to 0 % w/v (2% increments) 160 
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were prepared.  180 µl of each dilution was then added to all wells with in columns of a 96 161 
well microtiter plate. For example 180 µl 20 % w/v honey was added to wells A12 – H12, 180 162 
µl 18 % w/v honey was added to wells A11 – H11.  Finally 20 µl of a logarithmic phase culture 163 
of Ureaplasma was added to the all wells from A1 – A12.  1:10 dilutions from this were made 164 
across the plate from column one though to column eight as a means for determining the 165 
inhibitory activity of the Manuka honey at multiple concentrations of bacteria.  Plates were 166 
sealed with an adhesive sealing film and incubated statically at 37 oC until all colour change 167 
had ceased as determined visually (c.a 48 hours).  Colour changing units (CCU) were defined 168 
by determining the final dilution in which colour change had occurred, orange to red due to 169 
increased pH as a result of urea hydrolysis, therefore giving one CCU.  From this it was then 170 
possible to work back through the dilution gradient to determine the percentage of honey 171 
required to inhibit the growth of Ureaplasma at each CCU.  The methodology as previously 172 
described by Pereyre et al., was used to select for honey resistant mutants using the antibiotic 173 
susceptible strain HPA5 (Pereyre et al., 2007).  Statistical analysis was performed using 174 
Minitab version 17.0 to determine the statistical significance using a one-way ANOVA. 175 
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 Colour Changing Units (CCU) 
1 101 102 103 104 105 106 
U. urealyticum  
ATCC 27814 SV2 4.0 + 3.2 7.0 + 5.5 11.3 + 1.1 11.3 + 1.1 12.7 + 1.1 16.7 + 4.2 16.0 + * 
HPA99 7.3 + 4.2 8.7 + 3.1 9.3 + 2.3 10.7 + 1.2 12.7 + 1.2 17.0 + 4.2 N/A 
W11 8.7 + 4.2 10.0  + 3.5 10.0 + 3.5 12.0 + 3.5 13.3 + 3.1 14.0 + * 20.0 + * 
ATCC 27618 SV8 10.0 + 2.0 12.0 + 2.0 14.0 + 0.0 14.0 + 0.0 15.3 + 2.3 19.0 + 1.4 N/A 
U.u mean 7.5 + 2.6 9.4 + 2.1 11.1 + 2.1 12.0 + 1.4 13.5 + 1.2 16.7 + 2.1 18.0 + 2.8 
U. parvum  
HPA5 2.3 + 1.5 9.3 + 6.4 11.3 + 4.6 12.0 + 3.45 12.7 + 2.3 16.7 + 1.2 20.0 + * 
ATCC 700970 SV3 7.3 + 4.6 10.7 + 1.2 10.7 + 1.2 11.3 + 2.3 12.7 + 2.3 18.0 + * N/A 
ATCC 27818 SV6 2.3 + 1.6 11.3 + 1.1 12.7 + 1.2 12.7 + 1.2 13.3 + 1.2 15.3 + 3.0 12.0 + * 
HPA2 7.3 + 3.0 10.7 + 1.2 11.3 + 1.2 11.3 + 1.1 12.0 + 0.0 13.3 + 2.3 14.0 + 2.8 
U.p mean 4.8 + 2.9 10.5 + 0.8 11.5 + 0.8 11.8 + 0.7 12.7 + 0.5 15.8 + 2.0 15.3 + 4.2 
 237 
Table 1. Antimicrobial activity of Manuka honey against varying inoculum numbers of Ureaplasma urealyticum and 238 
Ureaplasma parvum isolates.  Results represent the mean Manuka honey minimum active dilution (% w/v) as well as standard 239 
deviation (triplicates). ‘*’ indicates only a single replicate was tested. CLSI guidelines recommend a level of 104 – 105 CCU for reliable 240 
antimicrobial susceptibility testing.  N/A = non-applicable. U.u = U. urealyticum. U.p = U. parvum 241 
 242 
 243 
 244 
 245 
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 Colour Changing Units (CCU) 
1 101 102 103 104 105 106 
Ureaplasma spp.  
ATCC 33175 SV9 (Tetr) 6.7 + 5.0 9.3 + 3.0 10.7 + 2.3 10.7 + 2.3 11.3 + 1.2 11.3 + 1.2 12.0 + 2.0 
UHWO10 (Eryr) 7.0 + 5.6 8.0 + 5.3 8.0 + 5.3 8.0 + 5.3 8.7 + 4.2 9.3 + 5.0 10.0 + 5.3 
HPA116 (Cipr) 8.0 + 3.6 9.3 + 4.6 10.0 + 3.5 10.7 + 4.2 11.3 + 4.6 12.0 + 3.5 12.0 + 3.5 
 246 
Table 2. Antimicrobial activity of Manuka honey against varying inoculum numbers of antibiotic resistant Ureaplasma spp.  247 
Results represent the mean Manuka honey minimum active dilution (% w/v) as well as standard deviation (triplicates). ATCC 33175 248 
SV9 (Tetr) represents a tetracycline resistant strain, UHWO10 (Eryr) represents an erythromycin resistant strain and HPA116 (Cipr) 249 
indicates a ciprofloxacin resistant strain.  CLSI guidelines recommend a level of 104 – 105 CCU for reliable antimicrobial susceptibility 250 
testing. 251 
 252 
